Systems and methods for the fabrication of tablets, including pharmaceutical tablets

A portable, self-contained system addresses the industry's need for flexible pharmaceutical tablet manufacturing by enabling seamless switching between dosages and compositions, reducing costs and equipment footprint, and allowing rapid production adaptation.

JP7577292B2Active Publication Date: 2024-11-05MASSACHUSETTS INST OF TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2019544025
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-01-24
Filing Date
2018-02-15
Publication Date
2024-11-05
Estimated Expiration
2038-02-15

AI Technical Summary

Technical Problem

The pharmaceutical industry faces challenges in transitioning to continuous manufacturing of pharmaceutical tablets due to the lack of a comprehensive infrastructure capable of producing diverse tablet compositions efficiently, requiring large investments and inflexible batch processes that are costly and difficult to adapt to changing demands.

Method used

A portable, self-contained system for manufacturing pharmaceutical tablets that allows seamless switching between different dosages and compositions without physical disconnection of unit operations, utilizing a compact setup with integrated modules for dispensing, blending, and tableting, enabling on-demand production of various tablets.

Benefits of technology

Facilitates flexible and efficient production of pharmaceutical tablets with different dosages and compositions, reducing costs and equipment footprint, and enabling rapid response to market demands, including the ability to produce small batches on demand.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577292000007
    Figure 0007577292000007
  • Figure 0007577292000008
    Figure 0007577292000008
  • Figure 0007577292000009
    Figure 0007577292000009
Patent Text Reader

Abstract

Systems and methods for fabricating ingestible pharmaceutical tablets are provided. Some of the systems and methods described herein are capable of producing tablets of different dosages without the need to fluidly connect or disconnect unit operations when switching from a tablet having a first dosage to a tablet having a second, different dosage. Some of the systems and methods described herein are capable of producing tablets compositionally, for example, tablets having different active pharmaceutical ingredients (APIs).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 460,626, entitled "SYSTEMS AND METHODS FOR THE FABRICATION OF TABLETS, INCLUDING PHARMACEUTICAL TABLETS," filed February 17, 2017, U.S. Provisional Application No. 62 / 619,638, entitled "SYSTEMS AND METHODS FOR THE FABRICATION OF TABLETS, INCLUDING PHARMACEUTICAL TABLETS," filed January 19, 2018, and U.S. Provisional Application No. 62 / 621,429, entitled "SYSTEMS AND METHODS FOR THE FABRICATION OF TABLETS, INCLUDING PHARMACEUTICAL TABLETS," filed January 24, 2018. The entire contents of each of these U.S. provisional applications are incorporated herein by reference.

[0002] Technical Field DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Systems and methods for fabricating tablets, including pharmaceutical tablets, are generally described. [Background technology]

[0003] background In recent years, the pharmaceutical and biotechnology industries have experienced a period of slowing growth and increasing costs associated with the development of new pharmaceutical products. Although individual processes involved in the manufacture of certain pharmaceutical products have transitioned to continuous-like processes, pharmaceutical facilities generally remain dependent on batch or semi-batch techniques to create complex chemical products. Current processes are typically adapted to manufacture a single, specific type of pharmaceutical tablet and generally require large, expensive, fixed set-ups. Although continuous processes have been proposed to provide numerous benefits, including reduced costs, the complete infrastructure and systems capable of complex continuous manufacturing of pharmaceutical tablets do not exist. The ability to fabricate pharmaceutical tablets (and possibly types of pharmaceutical tablets with different compositions) within a single self-contained system remains elusive. Summary of the Invention [Means for solving the problem]

[0004] overview Systems and methods are provided for fabricating tablets, including pharmaceutical tablets. Some of the systems and methods described herein are capable of producing tablets of different dosages without the need to fluidly connect or disconnect unit operations when switching from a tablet having a first dosage to a tablet having a second, different dosage. Some of the systems and methods described herein are capable of producing tablets compositionally, for example, tablets having different active pharmaceutical ingredients (APIs). The subject matter of the present invention optionally includes interrelated products, alternative solutions to a particular problem, and / or multiple different uses of one or more systems and / or articles.

[0005] According to one aspect, a method of making an ingestible pharmaceutical composition is provided. The method, in some embodiments, can include receiving instructions by a controller for a first tablet dose and a second tablet dose. The method can also include dispensing a first amount of a solid active pharmaceutical ingredient and dispensing a first amount of an additive. The method can also include blending the first amount of a solid active pharmaceutical ingredient and the first amount of an additive to form a first mixture having a volume less than 10 L. The method can also include forming a first tablet from the first mixture, dispensing a second amount of a solid active pharmaceutical ingredient, and dispensing a second amount of an additive. The method can also include blending the second amount of a solid active pharmaceutical ingredient and the second amount of an additive to form a second mixture, and forming a second tablet from the second mixture, where the dose of the active pharmaceutical ingredient of the first tablet is different from the dose of the active pharmaceutical ingredient of the second tablet.

[0006] According to another aspect, a method of making an ingestible pharmaceutical composition is provided. The method, in some embodiments, can include receiving instructions by a controller for a first tablet dose and a second tablet dose. The method can also include providing a first dispenser, a second dispenser, a blender, and a frame, with the first dispenser, the second dispenser, and the blender coupled to the frame. The method can also include dispensing a first amount of a solid active pharmaceutical ingredient, dispensing a first amount of an additive, blending the first amount of the solid active pharmaceutical ingredient and the first amount of the additive to form a first mixture, and forming a first tablet from the first mixture. The method can also include dispensing a second amount of a solid active pharmaceutical ingredient, dispensing a second amount of an additive, blending the second amount of the solid active pharmaceutical ingredient and the second amount of the additive to form a second mixture, and forming a second tablet from the second mixture.

[0007] According to yet another aspect, a method of making an ingestible pharmaceutical composition is provided. The method, in some embodiments, can include receiving instructions by a controller for a first drug type and a second drug type. The method can also include dispensing a first solid active pharmaceutical ingredient, dispensing a first additive, blending the first solid active pharmaceutical ingredient and the first additive to form a first mixture having a volume of less than 10 L, and forming a tablet from the first mixture. The method can also include dispensing a second solid active pharmaceutical ingredient having a different composition than the first solid active pharmaceutical ingredient, dispensing the second additive, blending the second solid active pharmaceutical ingredient and the second additive to form a second mixture, and forming a tablet from the second mixture.

[0008] According to yet another aspect, a system for making an ingestible pharmaceutical composition is provided. The system may, in some embodiments, include a plurality of dispensers, a first weighing scale configured to weigh materials dispensed from the plurality of dispensers, and a blender configured to receive and mix the materials dispensed from the plurality of dispensers to form a first mixture, the blender having a volume of less than 10 L.

[0009] According to yet another aspect, a system for making an ingestible pharmaceutical composition is provided, which in some embodiments can include a frame, a plurality of dispensers, a weighing scale configured to weigh materials dispensed from the plurality of dispensers, and a blender configured to receive and mix materials dispensed from the plurality of dispensers to form a first mixture, wherein the plurality of dispensers, the weighing scale, and the blender are coupled to the frame.

[0010] Other advantages and novel features of the present invention will become apparent from the following detailed description of various non-limiting embodiments of the present invention when considered in conjunction with the accompanying figures. In the event that the present specification and a document incorporated by reference include conflicting and / or inconsistent disclosure, the present specification shall control. In the event that two or more documents incorporated by reference include conflicting and / or inconsistent disclosure with respect to each other, the document having the later effective date shall control.

[0011] Non-limiting embodiments of the present invention will now be described, by way of example, with reference to the accompanying figures, which are schematic and are not intended to be drawn to scale. In these figures, each identical or nearly identical component shown is typically represented by a single number. For purposes of clarity, not every component is shown in every figure, nor every component of each embodiment of the present invention is shown, unless illustration is necessary to enable those skilled in the art to understand the invention. [Brief description of the drawings]

[0012] [Figure 1] FIG. 1 is a schematic diagram of a system for making pharmaceutical tablets according to one set of embodiments.

[0013] [Diagram 2] FIG. 2 is a block diagram of a method of making a pharmaceutical tablet according to one set of embodiments.

[0014] [Diagram 3] FIG. 3 is a perspective view of a system for making pharmaceutical tablets according to one set of embodiments.

[0015] [Figure 4] FIG. 4 is a front view of the system shown in FIG.

[0016] [Diagram 5] FIG. 5 is a photograph of a system for making pharmaceutical tablets.

[0017] [Figure 6] FIG. 6 is a perspective view of a system for making pharmaceutical tablets in a handheld configuration according to one set of embodiments.

[0018] [Figure 7] FIG. 7 is a perspective view of an array of dispensers according to one set of embodiments.

[0019] [Figure 8A] FIG. 8A is a graph showing the performance of the dispenser. [Figure 8B] FIG. 8B is a graph showing the performance of the dispenser. [Figure 8C] FIG. 8C is a graph showing the performance of the dispenser. [Figure 8D] FIG. 8D is a graph showing the performance of the dispenser.

[0020] [Figure 9] FIG. 9 is a perspective view of a material handling unit according to one set of embodiments.

[0021] [Figure 10] Figure 10 is a photograph of the material handling unit.

[0022] [Figure 11] FIG. 11 is a table showing the performance of the transport unit.

[0023] [Figure 12] FIG. 12 is a perspective view of a blender according to one set of embodiments.

[0024] [Figure 13] Figure 13 is a photograph of Brenda.

[0025] [Figure 14A] FIG. 14A is a photograph of the blender impeller. [Figure 14B] FIG. 14B is a photograph of the blender impeller. [Figure 14C]FIG. 14C is a perspective view of the blender impeller.

[0026] [Figure 15] FIG. 15 is a table showing blender mixing performance.

[0027] [Figure 16] FIG. 16 is a perspective view of a downstream process arrangement according to one set of embodiments.

[0028] [Figure 17] FIG. 17 is a photograph of the downstream process layout.

[0029] [Figure 18] FIG. 18 is a perspective view of a mixing blend dispenser according to one set of embodiments.

[0030] [Figure 19] FIG. 19 is a photograph of the mixing blend dispenser.

[0031] [Figure 20A] FIG. 20A is a graph showing the pipette performance. [Figure 20B] FIG. 20B is a graph showing the pipette performance.

[0032] [Figure 21] FIG. 21 is a perspective view of a tableting unit and weighing scale according to one set of embodiments.

[0033] [Figure 22] FIG. 22 is a photograph of the tablets produced by the tableting unit.

[0034] [Figure 23] FIG. 23 is a block diagram of an exemplary computing device that can be used to implement the method of making a pharmaceutical tablet.

[0035] [Figure 24]FIG. 24 is a block diagram of a method for making pharmaceutical tablets.

[0036] [Diagram 25] FIG. 25 is a photograph of a dispenser with a discharge chute and a vibration mechanism.

[0037] [Figure 26] FIG. 26 is a photograph of the dispenser discharge chute.

[0038] [Figure 27] FIG. 27 is a photograph of the vibration mechanism.

[0039] [Figure 28] FIG. 28 is a photograph of several glass beads that aid in dispensing of materials.

[0040] [Figure 29A] FIG. 29A is an optical microscope image of ibuprofen particles used in the tabletting process. [Figure 29B] FIG. 29B is an optical microscope image of diazepam particles used in the tabletting process.

[0041] [Diagram 30] FIG. 30 is a photograph of ibuprofen and diazepam tablets produced using the system for making pharmaceutical tablets.

[0042] [Figure 31A] FIG. 31A shows the dissolution results for the ibuprofen tablets prepared. [Figure 31B] FIG. 31B shows the dissolution results for the prepared diazepam tablets. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0043] Detailed Description SUMMARY OF THE DISCLOSURE Systems and methods relating to fabricating tablets, including pharmaceutical tablets, are generally described.

[0044] The ability to fabricate pharmaceutical tablets in a portable, self-contained, and / or easily reconfigurable system remains largely elusive. In the pharmaceutical industry, pharmaceutical tablets are typically made from large amounts of compounded blended batches on the kilo to ton scale. Such processes require significant investments in equipment, space, and materials. Also, with the significant costs associated with each batch, loss of a batch due to quality issues entails substantial monetary losses. For large production volumes, longer shelf lives of years or months may be required. As a result, comprehensive and rigorous end-product testing must be performed to measure shelf life / stability (such as active pharmaceutical ingredient degradability, sensitivity to temperature and moisture). To extend the shelf life of tablets produced in large quantities, coatings may be required. Developing a suitable coating formulation can be a significant challenge as coatings introduce potential issues such as stickiness, cracking, moisture resistance, effects on dissolution rate, and compatibility with the active pharmaceutical ingredient (API) and excipients. Such considerations may limit the acceptable API and / or excipient choices. Additional testing may be required given shelf life considerations. Suitable packaging may be designed and tested to sustain a long shelf life. This may introduce additional compatibility issues (e.g., between packaging and coating materials). Large production volumes may also entail the drawback of high costs and downtime associated with any product changeover. Thus, for example, a typical pharmaceutical facility may have difficulty responding flexibly to customer demands or responding to market demand for "orphan" drugs.

[0045] Described herein is a system and method for making finished dosage form pharmaceutical tablets. The unit can provide various benefits over traditional batch processes. The inventors have realized that in some cases the unit can provide various benefits, such as (1) helping to address local drug shortages, (2) providing a solution for drugs with short shelf life, (3) being reconfigurable to make multiple drug products, (4) being located where the drug products are needed, (5) starting to make drugs immediately on demand, bypassing the need to stockpile drugs, and / or (6) reducing the complexity of the formulation for products that require stability over several years.

[0046] According to one aspect, the system is a small, portable unit. In some embodiments, the system holds and processes much smaller volumes of material than that of a traditional batch process. In some embodiments, multiple components of the system are coupled together on a common frame, as opposed to large components being spread out on the floor of a facility independent of one another.

[0047] According to one aspect, the method involves using a system to make a first tablet and a second tablet, the two tablets being different from each other. In some embodiments, the two tablets may contain the same API but in different dosages. In some cases, the system can automatically switch between making two different dosages without any physical changes to the system components. In some embodiments, the first tablet can contain an API that is different in composition from the API of the second tablet. In some cases, when the system switches from making tablets containing one API to making tablets containing an API with a different composition, touch points in the system, i.e., components of the system that come into contact with the API, can be replaced with clean components.

[0048] According to one aspect, tablets can be made on demand, for example, a user can input instructions into the system specifying a desired dosage of tablets and / or a desired API. In some embodiments, the user can specify the number of tablets desired. In response, the system dispenses the appropriate types and amounts of APIs and excipients according to the user's instructions to form a blend mix for the tablets. In some embodiments, the system includes a controller that receives the user's instructions and controls the system components to perform steps according to the instructions.

[0049] In one set of embodiments, systems and methods related to making one or more pharmaceutical tablets are described. Figure 1 shows a schematic diagram of a system 1 according to one set of embodiments that can be used to make one or more pharmaceutical tablets. In some embodiments, the system comprises one or more modules. Each module can include at least one unit operation. The unit operations can be used to perform steps of a tablet making process.

[0050] In some embodiments, the system comprises multiple modules that interact with each other. For example, in certain embodiments, the system comprises multiple modules that interact with each other. In some such embodiments, each of the modules in the system can be used to perform one or more steps of a multi-step tablet making process.

[0051] For example, referring to FIG. 1, system 1 includes modules 110, 124, 130, 210, and 230. In some embodiments, module 110 includes multiple dispensers, module 124 includes weighing scales, module 130 includes a blender, module 210 includes a dispenser, and module 230 includes a tableting unit. The dispensers 110 can be used to dispense tablet material, the weighing scales 124 can be used to weigh the dispensed material, the blender 130 can be used to mix the dispensed material, the blend mix dispenser 210 can be used to dispense the blend mix, and the tableting unit 230 can be used to form tablets 2 from the blend mix. In some embodiments, the dispensed material from dispenser 110 is transported to blender 130. According to one aspect, the weighing and transport functions can be integrated into one material transport unit. In some embodiments, controller 300 controls the operation of the system. The controller 300 can receive feedback from and / or provide control instructions to one or more modules of the system. The dashed lines between the controller 300 and each module in FIG. 1 indicate that the controller 300 can communicate with one or more of the modules of the system. In some embodiments, the modules of the system (e.g., the dispenser, blender, carriage, etc.) can also communicate with each other, either by the controller and / or independently of the controller.

[0052] FIG. 2 shows a schematic diagram of a process for making a pharmaceutical tablet according to one set of embodiments. In such an embodiment, the API and additives are dispensed and then weighed. In some embodiments, the API and / or additives may be solids, such as in powder form. The API and additives may be dispensed and weighed at different times, such that the system is able to determine the mass of each type of dispensed material. For example, the system may first dispense the API and then weigh the dispensed API. The system may then dispense the additives and then weigh the dispensed additives. In some embodiments, the API may be dispensed into a carriage, and the additives may be dispensed into the same carriage holding the dispensed API. The system may determine the mass of the additives based on the increase in weight detected after the additives are added. In other embodiments, the materials may be weighed separately. For example, the API and additives may be weighed in different carriages. Or, the same carriage may be emptied between receipt of each type of material. For example, in some embodiments, the API is weighed first, and then the API is removed from the carriage. After the carriage is emptied, in some embodiments, the additive is received in the carriage and weighed. In the above discussion, it should be understood that the order of dispensing can be changed and reversed, for example, so that the additive is dispensed before the API. Alternatively, if multiple additives and / or APIs are used in the tablet, any dispensing order can be used.

[0053] In some embodiments, after weighing, the API and additives are delivered to a blender. In such embodiments, weighing is performed prior to delivery of the API and additives to the blender. However, in other embodiments, weighing can be performed within the blender itself. In either case, once the API and additives are in the blender, the blender mixes the API and additives together into a mixed blend. In some embodiments, the mixed blend is then dispensed into smaller individual portions and received by a tablet press, which forms and outputs the finished tablets. In some embodiments, the tablet press can compress the mixed blend using a direct compression method to form tablets. In some embodiments, the final tablet can be weighed to ensure the desired mass.

[0054] One exemplary embodiment of a system for making pharmaceutical tablets is shown in Figures 3 and 4, and a photograph of one system is shown in Figure 5. Each of the components described in this section is described in more detail in a later section. Tablet making system 1 includes multiple dispensers 110. In the embodiment of Figures 3 and 4, the system includes five dispensers 111, 112, 113, 114, and 115. In this embodiment, a weighing module includes a weighing scale 124, a carriage 120 that receives the material to be weighed, and an arm 122 that connects the weighing scale 124 to the carriage 120. In some embodiments, the weighing module also serves to transport the dispensed material to the blender. For example, in the embodiment shown in Figures 3-5, the weighing scale is coupled to an actuator 126, and thus the carriage 120 can be moved to various positions below each of the dispensers 110 and to the blender 130. In some embodiments, to facilitate delivery of material from the carriage 120 to the blender, the carriage is configured to tilt so that material in the carriage slides down into the blender. In some embodiments, the system can include a tilt mechanism 121 that tilts the carriage. In some embodiments, the blender 130 includes a rotating impeller that mixes the dispensed API and additives together into a blended mix.

[0055] The blended mix is ​​then transferred from the blender 130 to a dispenser 210. In some embodiments, the blender 130 is open at the bottom and flows into the underlying dispenser 210. In some embodiments, the blended mix dispenser 210 dispenses individual amounts of the blended mix into a tableting unit 230, which compresses the blended mix into tablets and ejects the tablets into a tablet output tray 238.

[0056] According to one aspect, the system can be divided into two process streams: an upper process stream 100 and a lower process stream 200. In the embodiment shown in Figures 3-5, the upper process stream 100 starts with a dispenser 110 and ends with a blender 130 that mixes the API and additives into a blended mix. The lower process stream 200 starts with a blend mix dispenser 210 that receives the blended mix and ends with a tableting unit 230 that forms and outputs tablets. The step of transferring the blended mix from the blender 130 to the blend mix dispenser 210 connects the upper and lower process streams. In the embodiment shown in Figures 3-5, this transfer step is done through an opening in the blender 130 to allow the blended mix in the blender 130 to drop into the dispenser 210 below. In some embodiments, the upper and lower process streams can operate simultaneously, possibly independently of each other. For example, tablets can be formed in the lower process stream while the API and additives are dispensed, weighed, and mixed in the blender in the upper process stream. The two process streams can be controlled by the same controller or by separate controllers.

[0057] In the embodiment shown in Figures 3-5, the upper and lower process streams occur in the same physical location, and in addition, with the blender discharging the blended mix directly into the underlying dispenser 210, the two process streams also directly interact with each other.

[0058] However, it should be understood that the upper and lower process streams can be physically separated from each other. For example, the two process streams can be carried out in separate facilities in different parts of the world. The upper process stream may provide a mixed blend that is transported to the location of the lower process stream, and the mixed blend is fed to the dispenser of the lower process stream. The two process streams can also be carried out in the same facility, but in separate locations, such that the blender of the upper process stream is not located directly above the dispenser of the lower process stream.

[0059] In some embodiments, the upper and lower process streams do not have to be spliced ​​together. For example, in some embodiments, the upper process stream can be fed by an independent tabletting stream. As another example, in some embodiments, the lower process stream can be fed by an independent blend stream.

[0060] According to one aspect, the upper and downstream processes are each an integrated system. In contrast to conventional large-scale batch processes in which components are spread out on the floor of the facility due to their large volume nature, for each of the upper and downstream processes, in some embodiments, the components are sized and positioned so that they can be coupled to a common frame, making the system compact and possibly portable. For example, in the embodiment shown in FIG. 3, the components of the upper process stream 100, such as the dispenser 110, the weigh scale 124, the carriage 120, and the blender 130, are coupled to the upper frame 10. As also seen in FIG. 3, the components of the lower process stream 200, such as the dispenser 210 and the tableting unit 230, are coupled to the lower frame 20.

[0061] According to one aspect, the tablet making system is a small, portable unit. In some embodiments, the tablet making system occupies a volume of less than 10,000 liters, less than 5000 liters, less than 2000 liters, or less than 1000 liters. As used herein, the "volume" of the system corresponds to the smallest rectangular prism that encloses all components of the system. In some embodiments, the tablet making system has a footprint of less than 10 square meters, less than 5 square meters, less than 2 square meters, or less than 1 square meter. In one embodiment, the tablet making system is about 72.4 cm x 53.3 cm x 134.6 cm (length x width x height).

[0062] According to one aspect, the tablet making system may be one complete integrated system, with both upper and lower process streams housed within one small portable unit. In some embodiments, the tablet making system may be located atop a rolling assembly, thus allowing the system to be easily moved and transported. In one exemplary embodiment shown in FIG. 6, the tablet making system 1 is integrated with a rolling assembly having wheels 42. The rolling assembly may include locks on the wheels that may be engaged to prevent inadvertent movement of the system and disengaged to allow movement of the system.

[0063] In some embodiments, the assembly can include a removable access cover that can be moved to provide access to the production system. In the exemplary embodiment shown in FIG. 6, the assembly includes a cover 30. The cover 30 can be mounted to the side of the system via an arm 32 that can be rotated up and down to allow the cover 30 to move between a closed position and an open position. In the open position, a user can access the components of the system 1 and can proceed with any suitable operation of the system, for example, for maintenance, cleaning, changing components, etc. In some embodiments, the cover 30 can be transparent to allow a user to view the tablet production system when the cover 30 is in the closed position. In some embodiments, a storage / equipment cabinet 40 can be provided with the production system 1.

[0064] In some embodiments, the system can be configured to produce pharmaceutical tablets on demand, at a scale of hundreds to thousands per day. Examples of different types of drugs that can be produced by such a unit include, but are not limited to, ibuprofen, doxycycline monohydrate, diphenhydramine hydrochloride, diazepam, ciprofloxacin HCl, azithromycin, and fluoxetine hydrochloride. In some embodiments, the same system can be configured to make two or more different drugs, even if the drugs are from different drug classes, have different chemical structures, bulk physical properties, flow behavior, and / or require different compounding strategies to make tablets. According to one aspect, the tablet making system is designed to accommodate a wide range of materials and tablet formulations.

[0065] Each of the components of the tablet making system is then discussed in more detail below.

[0066] One exemplary embodiment of a dispenser that can be used in the tablet making system is shown in FIG. 7. Multiple dispensers can be used, with each dispenser housing a different material. In some embodiments, the dispensers house APIs, excipients, or other suitable tablet ingredients. While five dispensers are used in the embodiment of FIG. 7, it should be understood that any suitable number of dispensers can be used. For example, 2, 3, 4, 5, 6 or more dispensers can be used.

[0067] In some embodiments, the dispenser is a volumetric dispenser whose dispensing rate is inferred from the dispenser speed based on prior calibration, while in other embodiments, the dispenser is a gravimetric dispenser whose dispensing rate is controlled based on direct gravimetric measurement.

[0068] In the embodiment shown in FIG. 7, the dispenser is an Orbetron 50 Series dispenser (ORBETRON, Hudson, WI). Such dispensers operate by rotating a feed disk within a storage container. An exemplary disk 500 is shown in FIG. 25. In some embodiments, the feed disk has small holes into which material can fall. Each rotation of the feed disk aligns material positioned within the holes of the feed disk with the outlet holes of the dispenser, thereby allowing the material within the disk holes to exit the dispenser. In this way, with each rotation, the feed disk allows a limited amount of material to exit the dispenser. In some embodiments, a "flicker" component can be added to the dispenser to aid in dispensing sticky materials. Such a component can help break powder bridges to promote flow.

[0069] The inventors recognize other configurations that may help reduce powder caking and / or otherwise prevent clogging of the dispenser.

[0070] In some embodiments, as shown in Figures 25-26, the dispenser can include a chute 510 downstream of the dispenser outlet. The chute can be attached directly to the dispenser outlet. The chute can assist in dispensing material out of the dispenser.

[0071] In some embodiments, a vibration mechanism 520 can be added to the dispenser, as shown in Figures 25 and 27. The vibration mechanism can help prevent caking of the material being dispensed and / or help prevent clogging of the dispenser outlet. The vibration mechanism can help reduce powder buildup on one or more components of the dispenser. The vibration mechanism can be positioned directly on the dispenser outlet itself, or can be positioned on a component attached to the dispenser outlet, such as the chute 510. One example of a vibration mechanism is the ADAFRUIT Vibrating Mini Motor Disk. In some embodiments, the operating voltage of the vibrating mini motor disk is 2-5 volts.

[0072] In some embodiments, beads can be added inside the dispenser to help reduce powder caking. The beads can be sized to stay in the dispenser without causing the dispenser to fail. For example, the beads can be larger than the dispenser outlet. In some embodiments, in dispensers that utilize a rotating disk, the beads can be sized larger than the space between the disk tines so that they do not fall into the space between the disk tines. These beads can move as the disk rotates, thereby breaking up any caking material and helping to keep the powder flowing in a continuous stream. An illustration of such beads is shown in FIG. 28, which shows a photograph of a number of glass beads. In some embodiments, the beads may be 5 mm in diameter. However, other diameter sizes can be used as well. In some embodiments, 10-30 grams of glass beads can be used. In some embodiments, about 18 grams of glass beads can be used.

[0073] In some embodiments, the dispenser can operate at rates as low as 2 grams / hour and as high as 5 kg / hour. The dispenser flow rate can be sufficient for even 1,000 doses per day.

[0074] It should be appreciated that other types of dispensers may also be used, such as a screw feeder, a vibrating feeder, a roller feeder, a belt feeder, etc.

[0075] 8A-8D show graphs illustrating the performance of the Orbetron 50 Series dispenser using an open loop configuration (i.e., no feedback from a weigh scale was used to control the dispenser). Testing was performed with API, free flowing additives, sticky additives, and blends. The results of the testing showed that higher variations in feed rate were observed for API and sticky additives, lower variations in feed rate were observed for free flowing additives and blends, and that the feed rate varied with changes in fill level or powder height.

[0076] In some embodiments, closed loop control of the dispensed powder can be included in the tablet making system to address these types of variations. As an example, a weigh scale can be used to provide closed loop feedback control. The placement of the weigh scale is discussed in more detail in the next section.

[0077] In some embodiments, the tablet making system can include a weigh scale to provide closed loop control of the dispensed powder. In some embodiments, the weigh scale takes the form of a load cell. It should be understood that other types of weigh scales can also be used, such as piezo-resistive sensors, force-return balances, etc.

[0078] In some embodiments, API and additives are delivered from multiple dispensers to a carriage suspended from a load cell. In some embodiments, API and additives from multiple dispensers are dispensed directly into a blender. In such an arrangement, the entire blender itself can be suspended from a load cell or other weighing scale so that the materials being dispensed into the blender can be weighed.

[0079] In some embodiments, the dispensed materials from the dispenser must be transported to a blender, hi some embodiments, the component of the tablet making system that performs the function of weighing the dispensed materials also performs the additional function of transporting the dispensed materials to the blender for mixing.

[0080] One exemplary embodiment of the weigh scale module is shown in FIG. 9, and a photograph of the actual weigh scale module is shown in FIG. 10. The module of FIGS. 9-10 includes a weigh scale 124 and a carriage 120 suspended from the weigh scale 124 via an arm 122. In the embodiment shown in FIGS. 9 and 10, the weigh scale 124 includes a load cell. In some embodiments, the weigh scale module also performs the additional function of transporting materials. In some embodiments, the module can include a linear actuator 126 to move the weigh scale 124, the arm 122, and the carriage 120 to different locations. In some embodiments, the carriage 120 can be commanded to move to any dispenser in any sequence, and the required amount of powder or other material can be dispensed at each dispenser location. The carriage 120 can then transport the material to a blender. In some embodiments, the module can include a track along which the components can slide.

[0081] The inventors have recognized that one potential challenge in transferring material from one vessel to another, especially when the material is a powder, is the tendency for some of the material to remain in the starting vessel, resulting in incomplete transfer of the material, which may result in improper ingredient ratios and / or waste.

[0082] In some embodiments, where an intermediate carriage is used to transport material from the dispenser to the blender, the carriage is positioned to tilt to aid in the transfer of material. In some embodiments, such as those of Figures 9 and 10, the carriage 120 can be pivotally mounted to an arm.

[0083] In some embodiments, the system can include a tilt mechanism, which can be located, for example, on the blender, in a stationary position above the blender, or on the carriage itself. When the carriage reaches the blender, the tilt mechanism can be activated to tilt the carriage. In the embodiment shown in Figures 3-5, the system includes a motorized tilt mechanism in the form of a forklift 121 positioned above the blender 130. When the carriage 120 reaches the blender, the forklift 121 lifts the rear end of the carriage and tilts the front edge of the carriage downward toward the blender's mixing vessel.

[0084] In other embodiments, the carriage tilt can be passive rather than a motorized tilt arrangement. For example, as the carriage moves towards the blender, it can interact with a physical obstacle, such as a tilted wedge, that pushes one end of the carriage upward, causing the carriage to tilt.

[0085] According to another aspect, materials can be dispensed from the dispenser into the carriage in a specific order to facilitate transfer of the materials from the carriage. In some embodiments, a controller controls the system to specifically dispense the least viscous materials into the carriage first. Without wishing to be bound by theory, sticky materials tend to leave more residue when contacting the generator vessel during transfer than less viscous materials. Thus, having the least viscous materials directly contact the carriage can help facilitate a cleaner transfer.

[0086] Tests were conducted on the amount of residue left behind in the material transport carriage when used to transfer powder material. As can be seen in the test results shown in Figure 11, approximately 1% of the starting powder remained attached to the carriage after transfer.

[0087] According to one aspect, the tablet ingredients are mixed until a desired amount of blend uniformity is reached. In some embodiments, the mixing can be performed by a blender.

[0088] One exemplary embodiment of a blender is shown in Figures 3, 4, 5, 12, and 13. As best seen in Figures 12-13, the blender 130 can include a mixing vessel 131, a motor 134, an actuator 133, and a gear box 132.

[0089] According to one aspect, the blender's mixing vessel can be sized to be much smaller than mixers used in conventional large volume batch processing. In some embodiments, the blender's mixing vessel can have a volume equal to or less than 10 L, 1 L, 500 mL, 200 mL, or 100 mL. In some embodiments, the blender's mixing vessel has a volume of about 200 mL. In some cases, the blender can mix about 50 grams of powder at a time at 40-50% capacity.

[0090] In some embodiments, materials dispensed from the dispenser 110 form a mixture in a blender having a total volume equal to or less than 10 L, 1 L, 500 mL, 200 mL, or 100 mL.

[0091] According to one aspect, the blender is configured to be easily cleanable and reconfigurable. In some embodiments, the blender includes a magnetic drive coupling, a quick-disconnect mount, and a sealed drive.

[0092] One exemplary embodiment of a blender impeller is shown in Figures 14A-C. The impeller includes a shaft 136 and a number of impeller vanes 137. The vanes 137 may be disposed at rotated angles relative to one another. Alternatively or additionally, for each group of vanes (one group on each side of the shaft), the vanes 137 may be positioned at different heights relative to one another and / or at different circumferential positions relative to one another along the drive shaft. In some embodiments, the impeller may create convective mixing to achieve a uniform blend.

[0093] In some embodiments, the blender can include a mechanism that allows for the release of contents through the bottom of the blender mixing vessel to facilitate transferring the blended materials out of the blender.

[0094] In some embodiments, the blender mixing vessel has an outlet valve (e.g., a bottom plug, etc.) that can be opened to allow the release of material. In one embodiment, a solenoid actuator pushes down on a shaft that is coaxial with the blender impeller shaft, moving the bottom plug downward so that the mixed blend can be transferred to a dispenser below.

[0095] The blender's mixing performance was tested using 4.48% Fluoxetine HCl + 0.5% SiO2 + 95.02% Corn Starch. As can be seen in the test results shown in Figure 15, after about 15 minutes of mixing, the RSD (relative standard deviation) reached less than 6%.

[0096] The lower process stream is now discussed: Figures 16 and 17 show one exemplary embodiment of the lower process stream, which includes a dispenser 210 and a tableting unit (which may include, in part, a tablet die 231 and a tablet punch 232).

[0097] In some embodiments, a second dispensing step is used to dispense the mixed blend into smaller individual portions of material, each of which is ultimately compressed to form a single tablet.

[0098] In one exemplary embodiment shown in FIG. 18 and FIG. 19, a blend mix dispenser 210 includes a hopper 212, a mechanical vibration unit 214, and a dispensing head 216. The blend mix from the blender 130 enters the hopper 212. In some embodiments, the vibration unit 214 operates based on a tapping mechanism that moves the vibration unit up and down via an actuator 215. In some embodiments, the tapping mechanism includes a mallet or other device that strikes the hopper itself or a component in contact with the hopper, thereby moving the hopper up and down. The dispensing head 216 can include one or more holes. The up and down movement of the hopper can force material out of the holes in the dispensing head 216. Without wishing to be bound by theory, the tapping mechanism may build microbridges of powder that break upon impact and then rebuild.

[0099] The dispensing performance of the dispenser was tested using dispensing heads with different hole sizes. As can be seen in the test results shown in Figure 20A, a linear relationship was observed between mass flow rate and number of holes. As can be seen in the test results shown in Figure 20B, measurements of mass delivered per tap (i.e., mass dispensed per tap) were found to be quite consistent and increased with increasing number of holes in the dispensing head.

[0100] It should be appreciated that other dispensing mechanisms may also be used, such as those described above in connection with the API and additive dispensers upstream from the blender.

[0101] In some embodiments, the tableting process includes a direct compression method in which powders (e.g., API powder and / or additive powders) and / or other tablet ingredients are pressed into a final tablet shape. In some embodiments, the tableting assembly can include a tablet die and tablet punches that work together to make a tablet. The punch can be lowered into the tablet die to compress the tablet ingredients to form a tablet. In some embodiments, the tableting assembly can also include a die actuator that moves the die from a receiving position, where the die receives a discrete amount of blended mix from the blended mix dispenser 210, to a compression position where the die is aligned with the tablet punch. In some embodiments, the die actuator can also move the die to a discharge position, where the finished tablet is discharged from the die.

[0102] In some embodiments, the system can include different tablet die sizes and punches depending on the tablet dose size. The system may automatically switch between different die and punch sizes or may require manual adjustments.

[0103] In some embodiments, after the tablet is formed and released, it is weighed by a weighing scale to determine if the tablet has a desired amount of mass. If the weighing scale determines that the tablet does not meet the mass requirement, the system can reject and discard the tablet.

[0104] One exemplary embodiment of a tablet press unit 230 is shown in Figure 16, and a portion of the tablet press unit is shown in Figure 21 (with the tablet punch 232 omitted from Figure 21). In some embodiments, the tablet press unit 230 can include a tablet die 231, a die carriage 220 (best seen in Figure 21), a die actuator 222, and a tablet punch 232.

[0105] In some embodiments, powder is first dispensed from the blend mix dispenser 210 into the tablet die 231. A die actuator 222 can move the tablet die 231 and die carriage 220 until the die 231 is positioned under the tablet punch 232 (the die carriage 220 is best seen in FIG. 21). A press 233 associated with the tablet punch 232 can be seen in FIG. 5. In some embodiments, a GAMLEN tablet press, punch, and dies (Gamlen, Nottingham, UK) can be used.

[0106] In some embodiments, with the tablet die 231 and tablet punch 232 aligned, the tablet punch 232 is lowered into the tablet die 231 where the tablet ingredients are compressed to form a tablet. For example, in Figure 16, the tablet punch 232 and tablet die 231 are shown in an aligned position. In some embodiments, the formed tablet is then discharged into a tablet output tray 238.

[0107] In some embodiments, the tablet punch is configured to apply a variable amount of compression pressure depending on hardness requirements, tablet formulation, and / or tablet size. In some embodiments, the controller can communicate to the tablet punch the appropriate compression pressure to apply. In some embodiments, one or more sensors, such as a transducer (e.g., a piezoelectric transducer), can be used to monitor and / or control the tablet press compression pressure. For example, in some embodiments, one or more sensors can be located within the tablet punch and / or tablet die during compression.

[0108] In some embodiments, such as those shown in Figures 5 and 21, a weigh scale 240 can be used to determine the weight of each tablet formed. In some embodiments, the tablet output tray 238 is positioned on a weigh scale, and the weigh scale detects the weight of each tablet formed by detecting the change in weight each time a tablet is output into the tray.

[0109] In some embodiments, if the tablet is measured to be of the weight expected for that tablet, the tablet is retained, and if the tablet is not of the expected weight, the tablet is discarded. A photograph of an exemplary resulting tablet 2 produced by the tablet production system is shown in FIG.

[0110] In some embodiments, the tableting unit requires only an upper punch 232 and no lower punch, although in other embodiments a lower punch may also be used.

[0111] In some embodiments, the techniques described herein may be implemented using one or more computing devices, including but not limited to network databases, storage systems, and central plant controllers. For example, a system may include a controller that includes one or more computing devices. The embodiments are not limited to the operation of any particular type of computing device.

[0112] 23 is a block diagram of an example computing device 1000 that can be used to implement any of the techniques described above. The computing device 1000 can include one or more processors 1001 and one or more tangible, non-transitory computer-readable storage media (e.g., memory 1003). The memory 1003 can store computer program instructions in the tangible, non-transitory computer-recordable medium that, when executed, implement any of the functionality described above. The processor 1001 can be coupled to the memory 1003 and can execute such computer program instructions to realize and perform the functionality.

[0113] The computing device 1000 may also include a network input / output (I / O) interface 1005, through which the computing device may communicate with other computing devices (e.g., over a network), and may also include one or more user I / O interfaces 1007, through which the computing device may provide output to and receive input from a user. The user I / O interfaces may include devices such as a keyboard, a mouse, a microphone, a display device (e.g., a monitor or touch screen), a speaker, a camera, and / or various other types of I / O devices.

[0114] The above-described embodiments can be implemented in any of a number of ways. For example, the embodiments can be implemented using hardware, software, or a combination thereof. When implemented in software, the software code can be executed on any suitable processor (e.g., a microprocessor) or group of processors, whether provided in a single computing device or distributed among multiple computing devices. It should be understood that any component or group of components performing the functions described above can be generally considered to be one or more controllers that control the functions discussed above. The one or more controllers can be implemented in a number of ways, such as dedicated hardware or general-purpose hardware (e.g., one or more processors) programmed with microcode or software to perform the functions described above. In some embodiments, a combination of programmable hardware and dedicated hardware can also be used.

[0115] In this regard, it should be understood that one implementation of the embodiments described herein comprises at least one computer-readable storage medium (e.g., RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital versatile disk (DVD) or other optical disk storage, magnetic cassette, magnetic tape, magnetic disk storage or other magnetic storage device, or other tangible non-transitory computer-readable storage medium) coded with a computer program (i.e., a plurality of executable instructions), which when executed on one or more processors performs the above-discussed functions of one or more embodiments. The computer-readable medium may be portable such that a program stored on the computer-readable medium can be loaded onto any computing device to implement aspects of the techniques discussed herein. In addition, it should be understood that reference to a computer program that, when executed, performs any of the above-discussed functions is not limited to application programs running on a host computer. Rather, the terms computer program and software are used in a general sense herein to refer to any type of computer code (e.g., application software, firmware, microcode, or any other form of computer instructions) that can be used to program one or more processors to implement aspects of the techniques discussed herein.

[0116] According to one aspect, tablets can be made on demand, for example, a user can input instructions into the system specifying a desired dosage and / or a desired drug type. In response, the system dispenses the appropriate types and amounts of APIs and excipients according to the user's instructions. In some embodiments, the system can include a controller that receives the user's instructions and controls the system components to carry out the instructions.

[0117] For example, the system can receive instructions to make 100 ibuprofen tablets with a dosage of 500 mg and 50 ibuprofen tablets with a dosage of 100 mg. The system controller receives the instructions and directs the various components of the system to make the tablets accordingly. For example, in some embodiments, the controller can direct a blend mix dispenser (a dispenser downstream from the blender) to dispense 100 doses of a mixed blend with a mass suitable for a 500 mg tablet, and then dispense 50 doses of a mixed blend with a mass suitable for a 100 mg tablet. In this way, in some embodiments, the system can seamlessly switch from making a first tablet dose to making a second tablet dose of the same drug without the need for interrupting the production or disconnecting / connecting modules or unit operations.

[0118] As another example, the system may receive instructions to make 100 tablets of a first drug type (e.g., ibuprofen) and 50 tablets of a second drug type with a different composition (e.g., azithromycin). The system controller receives the instructions and directs the various components of the system to make the tablets accordingly. In some embodiments, the dispensers upstream from the blender may already contain all of the APIs and additives required for both drugs. For example, three dispensers may hold the APIs and additives required to make the first drug type, and three other dispensers may hold the APIs and additives required to make the second drug type. In other embodiments, the dispensers holding the ingredients required for the second drug type are not connected to the system until after the making of the first drug type is finished.

[0119] In some embodiments, when switching between making different drug types, the "touch points" of the system can be replaced with clean components. The touch points of the system include any components of the system that come into contact with the dispensed tablet ingredients (e.g., API or excipients). Examples of touch points include the carriage, blender impeller, and mixing vessel, blend-mix dispenser hopper, tablet die, tablet press, and tablet output tray. These components can be replaced automatically by the system, manually by an operator, or by a mixture of both. However, making both types of drugs can still be considered to be performed on the same physical system with the overall infrastructure of the system remaining unchanged. For example, the frame to which the components are attached may remain the same, the weigh scales and actuators that move the carriage may remain the same, the blender motor and actuators may remain the same, the blend-mix dispenser actuators may remain the same, and / or the tablet die actuators may remain the same.

[0120] A schematic flow diagram of one such process according to one embodiment is shown in FIG. 24. First, the system receives dosage and / or drug type instructions at 410. Such instructions may be entered by a user, for example by the user interacting with a control panel of the system, by the user sending instructions from a remote location, etc. In some embodiments, the system may be pre-programmed with instructions. In response to these instructions, the system dispenses the appropriate API and excipients needed to make the specified drug type at 420. The dispensed materials are weighed at 430 and transported to a blender at 440. The blender creates a mixed blend at 450, and a dispenser dispenses an appropriately sized portion of the mixed blend at 460 to meet the specified dosage. A tablet press then receives the materials from the dispenser to form and eject tablets at 470. Step 480 indicates that the cycle begins again if new instructions are received.

[0121] In some embodiments, at least one of the dispensing, blending, and tableting steps is performed at least in part in response to instructions.

[0122] As mentioned above, some of the systems and methods described herein involve the use of an active pharmaceutical ingredient ("API"). As used herein, the term "active pharmaceutical ingredient" refers to an agent that is administered to a subject for the purpose of treating or preventing a disease, disorder, or other clinically recognized condition, and that has a clinically significant effect on the subject's body to treat and / or prevent the disease, disorder, or condition. Active pharmaceutical ingredients include, but are not limited to, those agents listed in the United States Pharmacopeia (USP), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, McGraw Hill, 2001; Katzung, B. (ed.), Basic and Clinical Pharmacology, McGraw-Hill / Appleton & Lange, 8th Edition (September 21, 2000); Physician's Desk Reference (Thomson Publishing); and / or The Merck Manual of Diagnosis and Therapy, its subsequent 17th Edition (1999) or 18th Edition (2006), Mark H. Beers and Robert Berkow (eds.), Merck Publishing Group, or for animals, The Merck Veterinary Manual, 9th Edition, Kahn, CA (ed.), Merck Publishing Group, 2005. Preferably, but not necessarily, the active pharmaceutical ingredient is one that has already been deemed safe and effective for human or animal use by the appropriate government or regulatory agency.For example, APIs approved for human use are listed by the FDA under 21C.FR §§330.5, 331-361, and 440-460, which are incorporated herein by reference, and APIs for veterinary use are listed by the FDA under 21C.FR §§500-589, which are incorporated herein by reference.All listed APIs are considered acceptable for use according to the present invention.

[0123] In certain embodiments, the active pharmaceutical ingredient is a small molecule. Exemplary active pharmaceutical ingredients include, but are not limited to, anti-cancer drugs, antibiotics, antivirals, anesthetics, anticoagulants, enzyme inhibitors, steroids, steroidal or non-steroidal anti-inflammatory drugs, antihistamines, immunosuppressants, antigens, vaccines, antibodies, decongestants, sedatives, opioids, pain relievers, analgesics, antipyretics, hormones, prostaglandins, and the like.

[0124] As used herein, the term "small molecule" refers to a molecule having a relatively low molecular weight, whether naturally occurring or artificially created (e.g., via chemical synthesis). Typically, small molecules are organic compounds (i.e., contain carbon). Small molecules can contain multiple carbon-carbon bonds, stereocenters, and other functional groups (e.g., amines, hydroxyls, carbonyls, heterocycles, and the like). In certain embodiments, the molecular weight of a small molecule is at most about 1,000 g / mol, at most about 900 g / mol, at most about 800 g / mol, at most about 700 g / mol, at most about 600 g / mol, at most about 500 g / mol, at most about 400 g / mol, at most about 300 g / mol, at most about 200 g / mol, or at most about 100 g / mol. In certain embodiments, the molecular weight of a small molecule is at least about 100 g / mol, at least about 200 g / mol, at least about 300 g / mol, at least about 400 g / mol, at least about 500 g / mol, at least about 600 g / mol, at least about 700 g / mol, at least about 800 g / mol, or at least about 900 g / mol, or at least about 1,000 g / mol. Combinations of the above ranges are also possible (e.g., at least about 200 g / mol and at most about 500 g / mol).

[0125] Non-limiting examples of APIs include diphenhydramine, ciprofloxacin, diazepam, fluoxetine, ibuprofen, doxycycline, and azithromycin. After reading this disclosure, one of ordinary skill in the art would be able to apply the synthesis methods and systems described herein to other active pharmaceutical ingredients.

[0126] As mentioned above, some of the systems and methods described herein can be used to make ingestible pharmaceutical compositions. In general, ingestible pharmaceutical compositions refer to compositions that include an active pharmaceutical ingredient and a pharma- ceutically acceptable excipient. As used herein, the term "pharma-ceutically acceptable excipient" refers to any type of non-toxic, inert solid, semi-solid, or liquid filler, diluent, encapsulating material, or formulation aid. Some non-limiting examples of materials that can serve as pharma-ceutically acceptable excipients include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository wax; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; Tween Detergents such as 80; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; water (e.g., pyrogen-free water); isotonic saline; citric acid, acetate, Ringer's solution; ethyl alcohol, and phosphate buffers, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, and coloring agents, release agents, coating agents, sweeteners, flavors and fragrances, preservatives and antioxidants can also be present in the composition according to the formulator's judgment. Other possible additives include lubricants and solubilizers.

[0127] In some embodiments, the ingestible pharmaceutical composition comprises at least about 2.5 mg, at least about 5.0 mg, or at least about 20 mg of active pharmaceutical ingredient per milliliter of pharma- ceutically acceptable excipient. In some embodiments, the active pharmaceutical ingredient is suspended in the pharma-ceutically acceptable excipient. In certain embodiments, the active pharmaceutical ingredient is suspended in the pharma-ceutically acceptable excipient. In some embodiments, the ingestible pharmaceutical composition is in the form of a tablet.

[0128] In some embodiments, the system is configured to produce at least about 1000 doses of API per day. In certain embodiments, the system is configured to produce at least about 2000 doses per day, at least about 4000 doses per day, at least about 8000 doses per day, at least about 10000 doses per day, or at least about 20000 doses per day. As generally understood by those skilled in the art, the term dose generally refers to the amount of active pharmaceutical ingredient administered to an organism (e.g., human, animal, plant, insect, and / or bacteria) to stimulate a biological response. In certain embodiments, the system is configured to produce at least about 20 grams / day, at least about 50 grams / day, at least about 100 grams / day, at least about 200 grams per day, or at least about 400 grams per day of the ingestible pharmaceutical composition.

[0129] In certain embodiments, the system is configured to produce relatively large quantities of active pharmaceutical ingredient in a small footprint. For example, in some cases, the system may be configured to produce at least about 5 grams of active pharmaceutical ingredient per square foot of footprint per day. In some embodiments, the system may produce at least about 7 g / day / ft of footprint per day. 2 , at least about 10 g / day / ft 2 , at least about 20 g / day / ft 2 , at least about 30 g / day / ft 2 , at least about 50 g / day / ft 2 , at least about 60 g / day / ft 2, at least about 70 g / day / ft 2 , at least about 90 g / day / ft 2 , at least about 100 g / day / ft 2 , at least about 120 g / day / ft 2 , at least about 150 g / day / ft 2 , or at least about 200 g / day / ft 2 In certain embodiments, the system is configured to produce at least about 1 gram of active pharmaceutical ingredient per cubic foot of housing (e.g., as described above) per day. For example, in some embodiments, the system is configured to produce at least about 2 g / day / ft of active pharmaceutical ingredient per volume of housing per day. 3 , at least about 3 g / day / ft 3 , at least about 4 g / day / ft 3 , at least about 5g / day / ft 3 , at least about 7 g / day / ft 3 , at least about 10 g / day / ft 3 , at least about 15 g / day / ft 3 , at least about 20 g / day / ft 3 , or at least about 25 g / day / ft 3 The present invention is configured to produce an active pharmaceutical ingredient of EXAMPLES

[0130] A tableting system for making pharmaceutical tablets was used to manufacture ibuprofen (IBU) tablets and diazepam (DIZ) tablets.

[0131] The system was split into an upper and a lower process stream. The upper process stream started with the feeding of the individual powders (API and excipients) and ended with the blend. The lower process stream started with the dispensing of the powder blend up to tablet compression. A direct compression method was used to make the tablets. These two process streams operated independently under high level software control.

[0132] The system dimensions are approximately 72.4 cm (length) x 53.3 cm (width) x 134.6 cm (height). API and additives were fed from multiple dispensers to a carriage consisting of a boat suspended from a load cell. The feeders were modified to dispense viscous API and additives when required. The carriage may be commanded to move to any dispenser in any sequence, and the required amount of powder may be dispensed at each feeder location. The carriage transferred the powder (any number of transfers may be possible) from the boat to a conical blender with an impeller. The blender mixed the powders via convection mixing to obtain a blend. After mixing, the blend was dispensed into the hopper of a blend mix dispenser with a tapping feeder. A CAPSUGEL (South Carolina, USA) dispensing head was used on the tapping feeder to regulate the amount of powder fed. The powder was then dispensed into a tablet press die in a predetermined amount (depending on the desired dose size). The actuator would slide the die into position under the actuating punch of a laboratory tablet press (Gamlen PCA-500D, Gamlen Tableting Ltd, UK). The blend was then compressed to form tablets. The tablets were ejected from the die and then transferred to a weighing station. Finally, the tablets were collected.

[0133] The materials used to make the ibuprofen and diazepam tablets are listed below in Table 1 along with their specific functions. [Table 1]

[0134] The physical properties of the ibuprofen and diazepam APIs are presented in Table 2 below. [Table 2]

[0135] A simplified approach in formulation development was explored by minimizing the number of excipients required for tabletting. Hence, only one filler / diluent, flow aid / glidant, and lubricant were considered as part of the formulation for both model drugs. Anhydrous lactose (SuperTab® 21AN) was used as a filler / diluent, fumed silica (CAB-O-SIL® M-5P) was used as a lubricant, magnesium stearate (Kosher Passover HyQual) was used as a lubricant, and 1,2-dichlorophenyl ether (1,2-dichlorophenyl ether) was used as a lubricant. TM ) was used as the lubricant. This grade of anhydrous lactose was selected as the filler in the formulation.

[0136] The compounded blend was used for the manufacture of tablets. The composition of the compound used is presented in Table 3 below. [Table 3]

[0137] The particle sizes of the API and excipients, except for fumed silica, are presented in Table 4 below. [Table 4]

[0138] Microscopy images showing the morphology of IBU and DIZ particles are shown in Figures 29A and 29B, respectively. The particle and bulk properties of IBU and DIZ are summarized in Table 4 above. Both IBU and DIZ were particulate, with diameters of d of 21.87 μm and 23.12 μm, respectively. 50 The microscopy images show IBU as plate-like rectangular particles (FIG. 29A), while DIZ particles are irregularly shaped aggregated particles (FIG. 29B).

[0139] The flow properties of the powder blends prepared for tablets were measured using a FT4 Powder Rheometer and are presented in Table 5 below. [Table 5]

[0140] Lactose, API, and silica were fed continuously into the blender for the IBU blend. Lactose was split into two equal amounts for the DIZ blend. One half was fed into the blender at the beginning and the other half was fed at the end of the feed sequence. The blender was operated at 80 RPM and all materials were blended for 26 minutes. Magnesium stearate was then added to the blender and blended for an additional 4 minutes at 80 RPM. Magnesium stearate was not added initially to prevent over-lubrication of the formulation. Within each blend batch, a total of 52.0 g of IBU blend and 43.6 g of DIZ blend were produced. Based on the measured adjusted bulk density of each final blend, 40% of the total blender volume was used for blending.

[0141] The final blend was transferred into a tapping feeder hopper. The powder was dispensed into a 10 mm die to produce tablets with a total weight of 340 mg and 250 mg for IBU and DIZ, respectively. The number of taps required to obtain the required fill weight was 53 (±5) for IBU and 35 (±5) for DIZ. The allowable weight variation was considered to be ±10% of the target tablet weight. The dispensed powder was compressed with a force of 450 kg using a flat round punch with a diameter of 10 mm to produce tablets. The punch speed was programmed at 1.0 mm / sec. Each tablet was weighed and its dimensions (diameter and thickness) were measured using a digital slide caliper (Fowler 54-100-000-2, Fowler Company Inc., Newton, MA). 22 tablets for IBU and 42 tablets for DIZ were produced and analyzed. Some of the ibuprofen and diazepam tablets produced are shown in FIG.

[0142] The properties (weight, tensile strength, evaluation, and content uniformity) of the resulting IBU and DIZ tablets were measured and are presented in Table 6 below. [Table 6]

[0143] The average tablet weights of 10 tablets produced are reported with %RSD values. The average weights of IBU and DIZ were 334.07 mg and 258.06 mg, respectively. The weight variations were within ±10% of the target tablet weights of 340 mg for IBU and 250 mg for DIZ. The RSD values ​​were below 3% for both drug tablets. The low RSD indicates uniform dispensing of the blend into the die and low tablet-to-tablet weight variation.

[0144] The average tensile strength of the IBU and DIZ tablets was 1.14 MPa and 0.52 MPa, respectively. The diameter and thickness of six tablets were measured. For the IBU tablets, the average values ​​for diameter and thickness were 10.06 (±0.03) mm and 3.8 (±0.12) mm, respectively. For the DIZ tablets, the average values ​​for diameter and thickness were 10.11 (±0.02) mm and 2.59 (±0.06) mm, respectively.

[0145] According to the USP-39 official monograph, an IBU / DIZ tablet must contain at least 90% and not more than 110% of the amount declared on the label to meet the evaluation standard. Similarly, based on 10 dosage units, if the calculated tolerance value of the active ingredient is equal to or less than 15.0, the product meets the USP quality standard. As shown in Table 6, the evaluation values ​​of the IBU and DIZ tablets are in the range of 90-110%. Since the tolerance value (AV) is below 15, both the IBU and DIZ tablets meet the content uniformity / weight variation standard.

[0146] Figures 31A and 31B show the dissolution results of the prepared IBU and DIZ tablets, respectively. Mean and standard deviation are shown (n=6). According to the USP monograph, 80% of the IBU should be dissolved within 60 minutes and 85% of the DIZ should be dissolved within 30 minutes. The time taken for 80% of the drug to dissolve (t 80 ) are 23 minutes and 4 minutes, respectively. Therefore, the dissolution results of both drug tablets meet the USP monographs.

[0147] Although several embodiments of the invention have been described and illustrated herein, various other means and / or structures for performing the functions and / or obtaining the results, and / or one or more of the advantages described herein, will readily occur to those skilled in the art, and each such variation and / or modification is deemed to be within the scope of the invention. More generally, all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and those skilled in the art will readily appreciate that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications in which the teachings of the invention are used. Many equivalents to the specific embodiments of the invention described herein will be recognized by those skilled in the art, or can be estimated using no more than routine experimentation. Thus, the above embodiments have been presented by way of example only, and it will be understood that, within the scope of the appended claims and their equivalents, the invention may be practiced otherwise than as specifically described and claimed. The invention is directed to each individual feature, system, article, material, and / or method described herein. In addition, any combination of two or more such features, systems, articles, materials, and / or methods is included within the scope of the present invention, unless such features, systems, articles, materials, and / or methods are mutually inconsistent.

[0148] As used herein, in the specification and claims, the indefinite articles "a" and "an" should be understood to mean "at least one," unless expressly indicated to the contrary.

[0149] As used herein, in the specification and claims, the phrase "and / or" should be understood to mean "either or both" of the elements so conjoined, i.e., elements that are conjointly present in some cases and disjointly present in other cases. Unless expressly indicated to the contrary, other elements may optionally be present other than the elements specifically identified by the "and / or" clause, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, a reference to "A and / or B," when used with open-ended language such as "comprising," can refer in one embodiment to A without B (optionally including elements other than B), in another embodiment to B without A (optionally including elements other than A), in yet another embodiment to both A and B (optionally including other elements), and so forth.

[0150] As used herein, and in the claims, "or" shall be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be construed to be inclusive, i.e., the inclusion of at least one, but more than one of a number or list of elements, and, where appropriate, additional items not in the list. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," shall refer to the inclusion of exactly one element of a number or list of elements. In general, as used herein, the term "or" shall be construed to indicate only exclusive alternatives (i.e., "one or the other, but not both") when preceded by an exclusive term, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0151] As used herein, in the specification and claims, the phrase "at least one" referring to a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also recognizes that elements other than those specifically identified in the list of elements to which the phrase "at least one" refers may optionally be present, whether related or unrelated to the specifically identified elements. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer to, in one embodiment, at least one (optionally including more than one) A in the absence of B (and optionally including elements other than B); in another embodiment, at least one (optionally including more than one) B in the absence of A (and optionally including elements other than A); in yet another embodiment, at least one (optionally including more than one) A and at least one (optionally including more than one) B (and optionally including other elements), etc.

[0152] In the claims, as well as in the above specification, all transitional phrases such as "comprising," "comprising," "including," "carrying," "having," "containing," "containing," "involving," "holding," and the like, are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Chapter 2111.03. In certain embodiments, for example, the following items are provided: (Item 1) 1. A method of making an ingestible pharmaceutical composition, the method comprising: receiving, by a controller, instructions regarding a first tablet dose and a second tablet dose; Dispensing a first quantity of a solid active pharmaceutical ingredient; Dispensing a first amount of an additive; blending the first amount of the solid active pharmaceutical ingredient and the first amount of the excipient to form a first mixture having a volume of less than 10 L; forming a first tablet from the first mixture; and dispensing a second amount of the solid active pharmaceutical ingredient; and Dispensing a second amount of the additive; and blending the second amount of the solid active pharmaceutical ingredient and the second amount of the excipient to form a second mixture; forming a second tablet from the second mixture; and wherein the dosage of the active pharmaceutical ingredient in the first tablet is different from the dosage of the active pharmaceutical ingredient in the second tablet. (Item 2) Weighing out the first amount of the solid active pharmaceutical ingredient and the first amount of the excipient; weighing said second amount of said solid active pharmaceutical ingredient and said second amount of said excipient; The method of claim 1, further comprising: (Item 3) 2. The method of claim 1, wherein the first mixture has a volume equal to or less than 1 L. (Item 4) 2. The method of claim 1, wherein the first mixture has a volume equal to or less than 500 mL. (Item 5) 2. The method of claim 1, wherein the first mixture has a volume equal to or less than 200 mL. (Item 6) 2. The method of claim 1, wherein the first mixture has a volume equal to or less than 100 mL. (Item 7) 2. The method of claim 1, wherein the first amount of the solid active pharmaceutical ingredient and the first amount of the additive are dispensed into a carriage. (Item 8) 8. The method of claim 7, further comprising weighing the first amount of the solid active pharmaceutical ingredient and the first amount of the additive with a weighing scale while the first amount of the solid active pharmaceutical ingredient and the first amount of the additive are in the carriage, the carriage being coupled to the weighing scale. (Item 9) 8. The method of claim 7, further comprising conveying, by said carriage, said first amount of said solid active pharmaceutical ingredient and said first amount of said additive to a blender. (Item 10) 9. The method of claim 8, further comprising conveying, by said carriage, said first amount of said solid active pharmaceutical ingredient and said first amount of said additive to a blender. (Item 11) 8. The method of claim 7, wherein the order of dispensing materials into the carriage is determined by the viscosities of the materials, with the least viscous material being dispensed into the carriage first. (Item 12) 2. The method of claim 1, further comprising dispensing a portion of the first mixture to form the first tablet. (Item 13) 13. The method of claim 12, further comprising compressing the first portion of the first mixture to form the first tablet. (Item 14) 2. The method of claim 1, further comprising weighing the first tablet and weighing the second tablet. (Item 15) 10. The method of claim 9, further comprising tilting the carriage to move the first amount of the solid active pharmaceutical ingredient and the first amount of the additive out of the carriage and into the blender. (Item 16) 13. The method of claim 1, wherein the blending is performed by a blender and further comprising opening a portion of the blender to release the first mixture. (Item 17) 17. The method of claim 16, further comprising moving the first mixture from the blender to a dispenser. (Item 18) 2. The method of claim 1, wherein the instructions for the second tablet dose are received at a different time than the instructions for the first tablet dose, and the step of dispensing the second amount of the solid active pharmaceutical ingredient is in response to the instructions for the second tablet dose. (Item 19) 2. The method of claim 1, wherein the second amount of the solid active pharmaceutical ingredient is different from the first amount of the solid active pharmaceutical ingredient. (Item 20) 2. The method of claim 1, wherein the second amount of the solid active pharmaceutical ingredient is the same as the first amount of the solid active pharmaceutical ingredient. (Item 21) 2. The method of claim 1, wherein the second amount of the additive is different from the first amount of the additive. (Item 22) 2. The method of claim 1, wherein the second amount of the additive is the same as the first amount of the additive. (Item 23) 2. The method of claim 1, wherein the solid active pharmaceutical ingredient is selected from the group consisting of ibuprofen, doxycycline monohydrate, diphenhydramine hydrochloride, diazepam, ciprofloxacin HCl, azithromycin, and fluoxetine hydrochloride. (Item 24) 8. The method of claim 7, further comprising moving the carriage between a first dispenser through which the solid active pharmaceutical ingredient is dispensed and a second dispenser through which the additive is dispensed. (Item 25) 8. The method of claim 7, wherein the carriage is slidably mounted to a track and moved along the track. (Item 26) Item 26. The method of item 25, wherein the carriage is moved along the track by an actuator. (Item 27) 2. The method of claim 1, wherein at least one of the dispensing, blending, and tableting steps is performed at least in part in response to said instructions. (Item 28) 2. The method of claim 1, wherein the second mixture has a volume equal to or less than 10 L. (Item 29) The method includes receiving, by a controller, instructions regarding a first medication type and a second medication type; dispensing a second solid active pharmaceutical ingredient; wherein the second solid active pharmaceutical ingredient is different in composition from the solid active pharmaceutical ingredient. The method according to item 1. (Item 30) 2. The method of claim 1, wherein the solid active pharmaceutical ingredient and the additives are dispensed from a plurality of dispensers and the blending is performed in a blender, and the plurality of dispensers and the blender are coupled to a frame. (Item 31) 1. A method of making an ingestible pharmaceutical composition, the method comprising: receiving, by a controller, instructions regarding a first tablet dose and a second tablet dose; Dispensing a first amount of a solid active pharmaceutical ingredient from a first dispenser; Dispensing a first amount of the additive from a second dispenser; blending the first amount of the solid active pharmaceutical ingredient and the first amount of the additive in a blender to form a first mixture; forming a first tablet from the first mixture; and dispensing a second amount of the solid active pharmaceutical ingredient from the second dispenser; dispensing a second amount of the additive from the second dispenser; blending the second amount of the solid active pharmaceutical ingredient and the second amount of the additive in the blender to form a second mixture; forming a second tablet from the second mixture; and Including, The method, wherein the first dispenser, the second dispenser, and the blender are coupled to the frame. (Item 32) Weighing out the first amount of the solid active pharmaceutical ingredient and the first amount of the excipient; weighing said second amount of said solid active pharmaceutical ingredient and said second amount of said excipient; 32. The method of claim 31, further comprising: (Item 33) 32. The method of claim 31, wherein the first mixture has a volume equal to or less than 10 L. (Item 34) 32. The method of claim 31, wherein the first mixture has a volume equal to or less than 1 L. (Item 35) 32. The method of claim 31, wherein the first mixture has a volume equal to or less than 500 mL. (Item 36) 32. The method of claim 31, wherein the first mixture has a volume equal to or less than 200 mL. (Item 37) 32. The method of claim 31, wherein the first mixture has a volume equal to or less than 100 mL. (Item 38) 32. The method of claim 31, wherein the first amount of the solid active pharmaceutical ingredient and the first amount of the additive are dispensed into a carriage. (Item 39) 39. The method of claim 38, further comprising weighing the first amount of the solid active pharmaceutical ingredient and the first amount of the additive with a weighing scale while the first amount of the solid active pharmaceutical ingredient and the first amount of the additive are in the carriage, the carriage being coupled to the weighing scale. (Item 40) 40. The method of claim 38, further comprising conveying, by said carriage, said first amount of said solid active pharmaceutical ingredient and said first amount of said additive to said blender. (Item 41) 40. The method of claim 39, further comprising conveying, by said carriage, said first amount of said solid active pharmaceutical ingredient and said first amount of said additive to said blender. (Item 42) Item 39. The method of item 38, wherein the order of dispensing materials into the carriage is determined by the viscosities of the materials, with the least viscous material being dispensed into the carriage first. (Item 43) 32. The method of claim 31, further comprising dispensing a portion of the first mixture to form the first tablet. (Item 44) 43. The method of claim 42, further comprising compressing the first portion of the first mixture to form the first tablet. (Item 45) 32. The method of claim 31, further comprising weighing the first tablet and weighing the second tablet. (Item 46) 40. The method of claim 39, further comprising tilting the carriage to move the first quantity of the solid active pharmaceutical ingredient and the first quantity of the additive out of the carriage and into the blender. (Item 47) 32. The method of claim 31, wherein the blending is performed by a blender and further comprising opening a portion of the blender to release the first mixture. (Item 48) Item 48. The method of item 47, further comprising moving the first mixture from the blender to a dispenser. (Item 49) 32. The method of claim 31, wherein the instructions for the second tablet dose are received at a different time than the instructions for the first tablet dose, and the step of dispensing the second amount of the solid active pharmaceutical ingredient is in response to the instructions for the second tablet dose. (Item 50) 32. The method of claim 31 , wherein the second amount of the solid active pharmaceutical ingredient is different from the first amount of the solid active pharmaceutical ingredient. (Item 51) 32. The method of claim 31 , wherein the second amount of the solid active pharmaceutical ingredient is the same as the first amount of the solid active pharmaceutical ingredient. (Item 52) 32. The method of claim 31, wherein the second amount of the additive is different from the first amount of the additive. (Item 53) 32. The method of claim 31, wherein the second amount of the additive is the same as the first amount of the additive. (Item 54) 32. The method of claim 31, wherein the solid active pharmaceutical ingredient is selected from the group consisting of ibuprofen, doxycycline monohydrate, diphenhydramine hydrochloride, diazepam, ciprofloxacin HCl, azithromycin, and fluoxetine hydrochloride. (Item 55) 40. The method of claim 38, further comprising moving the carriage between a first dispenser through which the solid active pharmaceutical ingredient is dispensed and a second dispenser through which the additive is dispensed. (Item 56) Item 39. The method of item 38, wherein the carriage is slidably mounted to a track and moved along the track. (Item 57) Item 57. The method of item 56, wherein the carriage is moved along the track by an actuator. (Item 58) 32. The method of claim 31, wherein at least one of the dispensing, blending, and tableting steps is performed at least in part in response to said instructions. (Item 59) 32. The method of claim 31, wherein the second mixture has a volume equal to or less than 10 L. (Item 60) The method includes receiving, by a controller, instructions regarding a first medication type and a second medication type; dispensing a second solid active pharmaceutical ingredient; wherein the second solid active pharmaceutical ingredient is different in composition from the solid active pharmaceutical ingredient. Item 32. The method according to item 31. (Item 61) 1. A method of making an ingestible pharmaceutical composition, comprising: receiving, by a controller, instructions regarding a first medication type and a second medication type; Dispensing a first solid active pharmaceutical ingredient; Dispensing a first additive; blending the first solid active pharmaceutical ingredient and the first excipient to form a first mixture having a volume of less than 10 L; forming a tablet from the first mixture; and dispensing a second solid active pharmaceutical ingredient, said second solid active pharmaceutical ingredient having a different composition than said first solid active pharmaceutical ingredient; Dispensing a second additive; and blending the second solid active pharmaceutical ingredient and the second excipient to form a second mixture; forming a tablet from the second mixture; and A method comprising: (Item 62) Weighing the first solid active pharmaceutical ingredient and the first excipient; Weighing the second solid active pharmaceutical ingredient and the second excipient. Item 62. The method of item 61, further comprising: (Item 63) Item 62. The method of claim 61, wherein the first mixture has a volume equal to or less than 1 L. (Item 64) Item 62. The method of item 61, wherein the first mixture has a volume equal to or less than 500 mL. (Item 65) Item 62. The method of claim 61, wherein the first mixture has a volume equal to or less than 200 mL. (Item 66) Item 62. The method of claim 61, wherein the first mixture has a volume equal to or less than 100 mL. (Item 67) Item 62. The method of item 61, wherein the first solid active pharmaceutical ingredient and the first additive are dispensed into a carriage. (Item 68) Item 68. The method of item 67, further comprising weighing the first solid active pharmaceutical ingredient and the first additive with a weighing scale while the first solid active pharmaceutical ingredient and the first additive are in the carriage, the carriage being coupled to the weighing scale. (Item 69) 68. The method of claim 67, further comprising conveying the first solid active pharmaceutical ingredient and the first additive to the blender by the carriage. (Item 70) 70. The method of claim 68, further comprising conveying the first solid active pharmaceutical ingredient and the first additive to the blender by the carriage. (Item 71) Item 68. The method of item 67, wherein the order of dispensing materials into the carriage is determined by the viscosities of the materials, with the least viscous material being dispensed into the carriage first. (Item 72) 62. The method of claim 61, further comprising weighing the first tablet and weighing the second tablet. (Item 73) Item 62. The method of item 61, wherein the first solid active pharmaceutical ingredient and the first additive are dispensed from a plurality of dispensers, the blending is performed in a blender, and the plurality of dispensers and the blender are coupled to a frame. (Item 74) 1. A system for making an ingestible pharmaceutical composition, the system comprising: A plurality of dispensers; a first weighing scale configured to weigh material dispensed from the plurality of dispensers; a blender configured to receive and mix the materials dispensed from the plurality of dispensers to form a first mixture; wherein the blender has a mixing vessel having a volume of less than 10 L. (Item 75) 75. The system of claim 74, wherein the mixing vessel has a volume equal to or less than 1 L. (Item 76) 75. The system of claim 74, wherein the mixing vessel has a volume equal to or less than 500 mL. (Item 77) 75. The system of claim 74, wherein the mixing vessel has a volume less than or equal to 200 mL. (Item 78) 75. The method of claim 74, wherein the mixing vessel has a volume equal to or less than 100 mL. (Item 79) Item 75. The system of item 74, further comprising a secondary dispenser configured to receive the first mixture from the blender and dispense individual amounts of the first mixture. (Item 80) 80. The system of claim 79, wherein the secondary dispenser is configured to move vertically up and down to dispense the discrete amounts of the first mixture. (Item 81) Item 81. The system of item 80, wherein the secondary dispenser is configured to operate via a tapping mechanism. (Item 82) Item 75. The system of item 74, further comprising a tableting unit including a tablet die and a tablet press configured to form a tablet from a portion of the first mixture. (Item 83) Item 75. The system of item 74, further comprising a carriage configured to transport materials from the plurality of dispensers to the blender. (Item 84) Item 84. The system of item 83, wherein the system further comprises a track and a linear actuator, the carriage being configured to be mounted to the track and moved along the track by the linear actuator. (Item 85) Item 84. The system of item 83, further comprising an arm coupling the carriage to the first weighing scale. (Item 86) Item 86. The system of item 85, wherein the carriage is pivotally mounted to the arm. (Item 87) Item 87. The system of item 86, further comprising a tilt actuator configured to tilt the carriage. (Item 88) Item 75. The system of item 74, wherein the first weighing scale comprises a load cell. (Item 89) 83. The system of claim 82, further comprising a second weighing scale positioned to weigh tablets from the tableting unit. (Item 90) Item 83. The system according to item 82, wherein the tableting unit is devoid of a lower punch. (Item 91) Item 75. The system of item 74, wherein the system further comprises a frame, the plurality of dispensers and the first weigh scale being coupled to the frame. (Item 92) Item 92. The system of item 91, wherein the blender is coupled to the frame. (Item 93) 75. The system of claim 74, further comprising a plurality of beads in at least one of the dispensers, the beads having a size larger than the outlet of the at least one dispenser. (Item 94) 1. A system for making an ingestible pharmaceutical composition, comprising: A frame, A plurality of dispensers; a weighing scale configured to weigh material dispensed from the plurality of dispensers; a blender configured to receive and mix the materials dispensed from the plurality of dispensers to form a first mixture; Equipped with The plurality of dispensers, the weigh scale, and the blender are coupled to the frame. (Item 95) Item 95. The system of item 94, wherein the blender has a mixing vessel having a volume equal to or less than 10 L. (Item 96) Item 96. The system of item 95, wherein the mixing vessel has a volume equal to or less than 1 L. (Item 97) Item 96. The system of item 95, wherein the mixing vessel has a volume equal to or less than 200 mL. (Item 98) Item 96. The method of item 95, wherein the mixing vessel has a volume equal to or less than 100 mL. (Item 99) Item 95. The system of item 94, further comprising a secondary dispenser configured to receive the first mixture from the blender and dispense individual amounts of the first mixture. (Item 100) Item 100. The system of item 99, wherein the secondary dispenser is configured to move vertically up and down to dispense the discrete amounts of the first mixture. (Item 101) Item 101. The system of item 100, wherein the secondary dispenser is configured to operate via a tapping mechanism. (Item 102) Item 95. The system of item 94, further comprising a tableting unit including a tablet die and a tablet press configured to form a tablet from a portion of the first mixture. (Item 103) Item 95. The system of item 94, further comprising a carriage configured to transport materials from the plurality of dispensers to the blender. (Item 104) Item 104. The system of item 103, wherein the system further comprises a track and a linear actuator, the carriage being configured to be mounted to the track and moved along the track by the linear actuator. (Item 105) Item 104. The system of item 103, further comprising an arm coupling the carriage to the first weighing scale. (Item 106) Item 106. The system of item 105, wherein the carriage is pivotally mounted to the arm. (Item 107) Item 107. The system of item 106, further comprising a tilt actuator configured to tilt the carriage. (Item 108) Item 95. The system of item 94, wherein the first weighing scale comprises a load cell. (Item 109) Item 103. The system of item 102, further comprising a second weighing scale positioned to weigh tablets from the tableting unit. (Item 110) Item 103. The system according to item 102, wherein the tableting unit is devoid of a lower punch.

Claims

1. 1. A method of making an ingestible pharmaceutical composition, the method comprising: Dispensing a first quantity of a solid active pharmaceutical ingredient from a first dispenser; Dispensing a first amount of the additive from a second dispenser; blending the first amount of the solid active pharmaceutical ingredient and the first amount of the additive in a blender to form a first mixture having a volume of less than 10 L; Receiving the first mixture in a secondary dispenser; dispensing discrete amounts of the first mixture by moving the secondary dispenser vertically up and down, wherein the secondary dispenser includes an area for receiving the first mixture and an opening through which the first mixture is dispensed, and wherein, during the vertical up and down movement of the secondary dispenser, the area for receiving the first mixture remains connected to the opening through which the first mixture is dispensed; forming a first tablet from the first mixture; and dispensing a second amount of the solid active pharmaceutical ingredient from the first dispenser; dispensing a second amount of the additive from the second dispenser; blending the second amount of the solid active pharmaceutical ingredient and the second amount of the additive in the blender to form a second mixture; receiving the second mixture in the secondary dispenser; forming a second tablet from the second mixture; and wherein a dosage of the active pharmaceutical ingredient in the first tablet is different from a dosage of the active pharmaceutical ingredient in the second tablet.

2. 1. A method of making an ingestible pharmaceutical composition, the method comprising: Dispensing a first quantity of a solid active pharmaceutical ingredient from a first dispenser; Dispensing a first amount of the additive from a second dispenser; blending the first amount of the solid active pharmaceutical ingredient and the first amount of the additive in a blender to form a first mixture; Receiving the first mixture in a secondary dispenser; dispensing discrete amounts of the first mixture by moving the secondary dispenser vertically up and down, wherein the secondary dispenser includes an area for receiving the first mixture and an opening through which the first mixture is dispensed, and wherein, during the vertical up and down movement of the secondary dispenser, the area for receiving the first mixture remains connected to the opening through which the first mixture is dispensed; forming a first tablet from the first mixture; and dispensing a second amount of the solid active pharmaceutical ingredient from the first dispenser; dispensing a second amount of the additive from the second dispenser; blending the second amount of the solid active pharmaceutical ingredient and the second amount of the additive in the blender to form a second mixture; receiving the second mixture in the secondary dispenser; forming a second tablet from the second mixture; and Including, The method, wherein the first dispenser, the second dispenser, and the blender are coupled to a frame.

3. Weighing out the first amount of the solid active pharmaceutical ingredient and the first amount of the excipient; weighing said second amount of said solid active pharmaceutical ingredient and said second amount of said excipient; The method of claim 1 or 2, further comprising:

4. 4. The method of any of claims 1-3, wherein a second solid active pharmaceutical ingredient is blended with said first amount of said solid active pharmaceutical ingredient and said first amount of said additive to form said first mixture, and wherein said second solid active pharmaceutical ingredient differs in composition from said solid active pharmaceutical ingredient.

5. 4. The method of any one of claims 1 to 3, wherein a second solid active pharmaceutical ingredient is blended with said second amount of said solid active pharmaceutical ingredient and said second amount of said additive to form said second mixture, and wherein said second solid active pharmaceutical ingredient differs in composition from said solid active pharmaceutical ingredient.

6. 4. The method according to any one of claims 1 to 3, wherein after forming the second tablet, the method further comprises: dispensing a second solid active pharmaceutical ingredient from a third dispenser; dispensing a second additive from a fourth dispenser; blending the second solid active pharmaceutical ingredient and the second excipient to form a third mixture; receiving the third mixture in the secondary dispenser; forming a third tablet from the third mixture; and Including, wherein the second solid active pharmaceutical ingredient has a different composition than the solid active pharmaceutical ingredient; method.

7. The method of any of claims 1 to 6, wherein the second amount of the solid active pharmaceutical ingredient is different from the first amount of the solid active pharmaceutical ingredient.

8. The method of any of claims 1 to 7, wherein the second amount of the solid active pharmaceutical ingredient is the same as the first amount of the solid active pharmaceutical ingredient.

9. 1. A method of making an ingestible pharmaceutical composition, comprising: Dispensing a first solid active pharmaceutical ingredient from a first dispenser; Dispensing a first additive from a second dispenser; blending the first solid active pharmaceutical ingredient and the first excipient in a blender to form a first mixture having a volume of less than 10 L; Receiving the first mixture in a secondary dispenser; dispensing discrete amounts of the first mixture by moving the secondary dispenser vertically up and down, wherein the secondary dispenser includes an area for receiving the first mixture and an opening through which the first mixture is dispensed, and wherein, during the vertical up and down movement of the secondary dispenser, the area for receiving the first mixture remains connected to the opening through which the first mixture is dispensed; forming a tablet from the first mixture; and dispensing a second solid active pharmaceutical ingredient from said first dispenser or from a third dispenser, said second solid active pharmaceutical ingredient having a different composition than said first solid active pharmaceutical ingredient; Dispensing a second additive from the second dispenser or from a fourth dispenser; blending the second solid active pharmaceutical ingredient and the second excipient in the blender to form a second mixture; receiving the second mixture in the secondary dispenser; forming a tablet from the second mixture; and A method comprising:

10. The method of any one of claims 3 to 8, wherein the blending is performed by a blender coupled to a frame.

11. 11. The method of any one of claims 1, 2, 9 or 10, further comprising moving the first mixture from the blender to the secondary dispenser.

12. 12. The method of any of claims 1 to 8 and claim 11 insofar as claim 11 is dependent on claim 1 or 2, wherein the first amount of the solid active pharmaceutical ingredient, the first amount of the additive, the second amount of the solid active pharmaceutical ingredient, and the second amount of the additive are dispensed from a plurality of dispensers, the plurality of dispensers being coupled to a frame.

13. 12. The method of claim 11, insofar as claim 9 or claim 11 is dependent on claim 9, wherein the first solid active pharmaceutical ingredient, the first additive, the second solid active pharmaceutical ingredient, and the second additive are dispensed from a plurality of dispensers, the plurality of dispensers being coupled to a frame.

14. The method of any of claims 1 to 13, wherein the solid active pharmaceutical ingredient is selected from the group consisting of ibuprofen, doxycycline monohydrate, diphenhydramine hydrochloride, diazepam, ciprofloxacin HCl, azithromycin, and fluoxetine hydrochloride.

Citation Information

Patent Citations

  • Vibrating feeder using piezoelectric vibrator

    JP1987235115A

  • Compression molding machine provided with granular body fixed quantity mixing and supplying device

    JP1988005900A

  • Device for automatically forming tablet

    JP1997271996A

  • Medicine packaging apparatus

    JP2002362501A

  • Powder dispensing device

    JP2013245008A